Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 5/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4786693 | 0.84 | DHODH (0.46) | DHODHNAPRTRORC | |
| SCHEMBL4738771 | 0.83 | ACMSD (0.51) | DHODHPARP1XDHSLC22A12FABP4 | |
| SCHEMBL4733527 | 0.81 | XDH (0.44) | PARP1XDHSLC22A12FABP4FABP3 | |
| SCHEMBL4648140 | 0.80 | GRIA2 (0.40) | DHODHPARP1CYP2C19GRIA2 | |
| SCHEMBL4734867 | 0.78 | PARP1 (0.55) | PARP1XDHSLC22A12FABP4FABP3 | |
| SCHEMBL4738866 | 0.78 | MCL1 (0.51) | DHODHPARP1XDHSLC22A12FABP4 | |
| SCHEMBL4739374 | 0.77 | MCL1 (0.59) | XDHSLC22A12 | |
| SCHEMBL4733776 | 0.76 | PARP1 (0.52) | PARP1XDHSLC22A12FABP4FABP3 | |
| SCHEMBL4733757 | 0.76 | MCL1 (0.53) | PARP1XDHSLC22A12FABP4FABP3 | |
| SCHEMBL4737359 | 0.75 | PARP1 (0.49) | DHODHPARP1XDHSLC22A12FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | claimed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | claimed |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | DHODH 3192/4885NAPRT 3189/4885PARP1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.